Age and Response to Flu Vaccines
NCT03328325
Completed
The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline, day 7, 28 and 90. The primary objective of... Read More
Gender:
ALL
Ages:
Between 9 years and 99 years
Trial Updated:
04/29/2021
Locations: Rochester General Hospital - Infectious Disease Unit, Rochester, New York +1 locations
Conditions: Influenza, Influenza Immunisation
Register for Updates
Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
NCT00787826
Unknown
This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2021
Locations: U.S. Army Medical Research Institute of Infectious Diseases, Fort Deterick, Maryland
Conditions: Tularemia
Register for Updates
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
NCT03481816
Completed
Background: Metastatic castration resistant prostate cancer (mCRPC) keeps growing even when the amount of testosterone in the body is reduced to very low levels. mCRPC is incurable. Researchers want to develop vaccines to teach the immune system to target and kill cancer cells. They want to test three of these vaccines (ETBX-071, ETBX-061, and ETBX-051) against mCRPC. Objective: To test the safety of combination ETBX-071, ETBX-061, and ETBX-051 and to study their effects on the immune system.... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostatic Cancer
Register for Updates
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
NCT00985426
Completed
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2021
Locations: Clinical Research Associates of Tidewater, Norfolk, Virginia
Conditions: Chronic Kidney Disease
Register for Updates
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
NCT02045836
Completed
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Golden, Colorado +8 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
NCT02075515
Completed
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Mesa, Arizona +7 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT01976520
Unknown
This Phase I trial studies the safety and efficacy of vaccine therapy in treating patients with previously untreated chronic lymphocytic leukemia. Liposome-based vaccines containing an extract of a person's cancer cells and the immunostimulant interleukin-2 may help the body to build an effective immune response to kill cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2021
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois
Conditions: Chronic Lymphocytic Leukemia (CLL)
Register for Updates
Pneumococcal Conjugate Vaccine in Aging Renal Transplant
NCT03802994
Terminated
The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. The investigators will study differences in the kind of B cells and markers on the B cells that are known to be important in the response to the pneumonia vaccine in aging renal transplant and aging d... Read More
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
04/06/2021
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina +1 locations
Conditions: Renal Transplantation, Aging
Register for Updates
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
NCT00118274
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclophosphamide may also stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with cyclophosphamide after surgery may cause a stronger immune response... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/25/2021
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania +2 locations
Conditions: Melanoma (Skin)
Register for Updates
FLUAD® vs. Fluzone® High-Dose Study
NCT03183908
Completed
The overall aim of the study is to compare safety and immunogenicity of inactivated influenza vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone® High-Dose) vaccine in persons ≥65 years (20% aged ≥80 years). A prospective, randomized, blinded clinical trial that will be conducted during the 2017/2018 and 2018/2019 influenza seasons. During each season, approximately 220 older adults will be enrolled at Duke University Medical Center and 140 older adults at Boston... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/04/2021
Locations: Centers for Disease Control and Prevention, Atlanta, Georgia +3 locations
Conditions: Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Register for Updates
Safety of LAIV4 in Children With Asthma
NCT03600428
Completed
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injection of quadrivalent IIV4 (IIV4).
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
02/25/2021
Locations: Duke University Medical Center, Durham, North Carolina +2 locations
Conditions: Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
Register for Updates
A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine
NCT02776761
Completed
This is a single-center, randomized, single-blinded study of the Hantaan virus HTNV DNA vaccine alone, Puumala virus PUUV DNA vaccine alone, and mixed Hantaan/Puumala HTNV/PUUV DNA vaccines delivered intramuscularly IM by the needle-free PharmaJet Stratus DSJI device.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/10/2021
Locations: WRAIR Clinical Trials Center, Silver Spring, Maryland
Conditions: Hantaan Virus
Register for Updates